References
- Isaacson P G, Piris M A, Catovski D, Swerd Low S, Montserrat E, Berger F, . Splenic marginal zone lymphoma. Tumors of Haematopoietic and Lymphoid tissues. WHO Classification of Tumors, E S Jaffe, N L Harris, H Stein, J W Vardiman, et al. IARC Press, LyonFrance 2001; 135–137
- Murakami H, Irisawa H, Saitoh T, Matsushima T, Tamura J, Sawamura M, et al. Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol 1997; 56: 173–178
- Rand J H. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90: 29–37
- Rand J H, Wu X X, Lapinski R, van Heerde W L, Reutelingsperger C P, Chen P P, et al. Detection of antibody-mediated reduction of annexinA5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104: 2783–2790
- Lieby P, Poindron V, Roussi S, Klein C, Knapp A, Garaud J, et al. Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood 2004; 104: 1711–1715
- Bennett M, Sharma K, Yegena S, Gavish I, Dave H P, Schechter G P. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90: 856–858
- Treon S P, Branagan A R, Hunter Z, Santos D, Tournhilac O, Anderson K C. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004; 15: 1481–1483
- Gordan L N, Grow W B, Pusateri A, Douglas V, Mendenhall N P, Lynch J W. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23: 1096–1102